Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131080 | 0.76 | MAPK1 (0.55) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28962436 | 0.76 | MAPK1 (0.55) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8883107 | 0.74 | MAPK1 (0.44) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL133155 | 0.73 | MEN1 (0.52) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3289050 | 0.73 | MAPK1 (0.52) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL131366 | 0.73 | ALDH1A1 (0.59) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL130420 | 0.73 | KMT2A (0.59) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4073489 | 0.73 | MAPK1 (0.74) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL58539 | 0.73 | MAPK1 (0.57) | MAPK1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL4507358 | 0.73 | MAPK1 (0.52) | MAPK1MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0582455-B1 | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO INC (US) | 2000-11-02 | — | — | EP | claimed |
| WO-2024128000-A1 | ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE | 東京応化工業株式会社 | 2024-06-20 | — | — | WO | disclosed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| EP-2990404-B1 | TETRAZOLINONE COMPOUND AND USE OF SAME | SUMITOMO CHEMICAL CO (JP) | 2020-05-27 | — | — | EP | disclosed |
| EP-3153508-B1 | NAPHTHOFURAN DERIVATIVES FOR USE AS ANTICANCER AGENTS | KYOTO PHARMA IND (JP) | 2020-03-18 | — | — | EP | disclosed |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-10377730-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180265489-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-09-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1216980-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6162828-A | IMMUNOLOGY; ANTIINFLAMMATORY AGENTS; ANTITUMOR AGENTS; BONE DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-0582455-B1 | Benzoxazinones as inhibitors of HIV reverse transcriptase | MERCK & CO INC (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-0820464-A2 | CYSTEINE PROTEASE INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996030395-A2 | CYSTEINE PROTEASE INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317630-A1 | ANTICANCER AGENT | TP53, NTPCR, NQO1 | MAPK1 2224/4885MEN1 788/4885KMT2A 1928/4885 |
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | MAPK1 2224/4885MEN1 788/4885KMT2A 1928/4885 |
| US-20180265489-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | MAPK1 2204/4885MEN1 1182/4885KMT2A 1828/4885 |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MAPK1 698/4885MEN1 4091/4885KMT2A 2774/4885 |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | MAPK1 2204/4885MEN1 1182/4885KMT2A 1828/4885 |
| US-10689355-B2 | Anticancer agent | TP53, NTPCR, NQO1 | MAPK1 2224/4885MEN1 788/4885KMT2A 1928/4885 |
| US-10377730-B2 | Anticancer agent | TP53, NTPCR, NQO1 | MAPK1 2224/4885MEN1 788/4885KMT2A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.